GH Research (NASDAQ:GHRS) Stock Price Down 6.7% – Time to Sell?

Posted by Donald Scott on Jan 3rd, 2025

GH Research PLC (NASDAQ:GHRS – Get Free Report)’s stock price traded down 6.7% during trading on Wednesday . The stock traded as low as $6.95 and last traded at $7.00. 91,514 shares changed hands during trading, an increase of 18% from the average session volume of 77,875 shares. The stock had previously closed at $7.50.

Analyst Ratings Changes

GHRS has been the subject of several recent research reports. Canaccord Genuity Group decreased their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of GH Research in a report on Wednesday, November 20th.

Check Out Our Latest Research Report on GH Research

GH Research Stock Up 13.0 %

The business has a 50 day moving average of $8.33 and a 200 day moving average of $9.33. The company has a market capitalization of $411.54 million, a P/E ratio of -10.01 and a beta of 0.78.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP grew its position in GH Research PLC (NASDAQ:GHRS – Free Report) by 19.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,966,726 shares of the company’s stock after purchasing an additional 656,163 shares during the quarter. GH Research comprises approximately 16.7% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 3rd biggest holding. Lynx1 Capital Management LP owned about 7.62% of GH Research worth $46,252,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).